PACS gene family-related neurological diseases: limited genotypes and diverse phenotypes

Li C, Li L, Yang M, Zeng L, Sun L. PACS-2: a key regulator of mitochondria-associated membranes (MAMs). Pharmacol Res. 2020;160:105080.

Wan L, Molloy SS, Thomas L, Liu G, Xiang Y, Rybak SL, et al. PACS-1 defines a novel gene family of cytosolic sorting proteins required for trans-Golgi network localization. Cell. 1998;94:205–16.

Simmen T, Aslan JE, Blagoveshchenskaya AD, Thomas L, Wan L, Xiang Y, et al. PACS-2 controls endoplasmic reticulum-mitochondria communication and Bid-mediated apoptosis. EMBO J. 2005;24:717–29.

Olson HE, Jean-Marçais N, Yang E, Heron D, Tatton-Brown K, van der Zwaag PA, et al. A recurrent de novo PACS2 heterozygous missense variant causes neonatal-onset developmental epileptic encephalopathy, facial dysmorphism, and cerebellar dysgenesis. Am J Hum Genet. 2018;102:995–1007.

Dentici ML, Barresi S, Niceta M, Ciolfi A, Trivisano M, Bartuli A, et al. Expanding the clinical spectrum associated with PACS2 mutations. Clin Genet. 2019;95:525–31.

Mizuno T, Miyata R, Hojo A, Tamura Y, Nakashima M, Mizuguchi T, et al. Clinical variations of epileptic syndrome associated with PACS2 variant. Brain Dev. 2021;43:343–7.

Olson HE, Jean-Marçais N, Yang E, Heron D, Tatton-Brown K, van der Zwaag PA, et al., A recurrent de novo PACS2 heterozygous missense variant causes neonatal-onset developmental epileptic encephalopathy, facial dysmorphism, and cerebellar dysgenesis. Am J Hum Genet. 2018;103:631.

Terrone G, Marchese F, Vari MS, Severino M, Madia F, Amadori E, et al. A further contribution to the delineation of epileptic phenotype in PACS2-related syndrome. Seizure. 2020;79:53–5.

Zhu T, Gong X, Bei F, Ma L, Chen Y, Zhang Y, et al. Application of next-generation sequencing for genetic diagnosis in neonatal intensive care units: results of a multicenter study in China. Front Genet. 2020;11:565078.

Wu MJ, Hu CH, Ma JH, Hu JS, Liu ZS, Sun D. Early infantile epileptic encephalopathy caused by PACS2 gene variation: three cases report and literature review. Zhonghua Er Ke Za Zhi. 2021;59:594–9 (in Chinese).

Wang T, Hoekzema K, Vecchio D, Wu H, Sulovari A, Coe BP, et al. Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders. Nat Commun. 2020;11:4932.

Monies D, Abouelhoda M, Assoum M, Moghrabi N, Rafiullah R, Almontashiri N, et al. Lessons learned from large-scale, first-tier clinical exome sequencing in a highly consanguineous population. Am J Hum Genet. 2019;104:1182–201.

Jiang T, Gao J, Jiang L, Xu L, Zhao C, Su X, et al. Application of trio-whole exome sequencing in genetic diagnosis and therapy in Chinese children with epilepsy. Front Mol Neurosci. 2021;14:699574.

Bruel AL, Nambot S, Quéré V, Vitobello A, Thevenon J, Assoum M, et al. Increased diagnostic and new genes identification outcome using research reanalysis of singleton exome sequencing. Eur J Hum Genet. 2019;27:1519–31.

Schuurs-Hoeijmakers JH, Oh EC, Vissers LE, Swinkels ME, Gilissen C, Willemsen MA, et al. Recurrent de novo mutations in PACS1 cause defective cranial-neural-crest migration and define a recognizable intellectual-disability syndrome. Am J Hum Genet. 2012;91:1122–7.

Seto MT, Bertoli-Avella AM, Cheung KW, Chan KY, Yeung KS, Fung JL, et al., Prenatal and postnatal diagnosis of Schuurs-Hoeijmakers syndrome: case series and review of the literature. Am J Med Genet A. 2021;185:384–9.

Tenorio-Castaño J, Morte B, Nevado J, Martinez-Glez V, Santos-Simarro F, García-Miñaúr S, et al. Schuurs-Hoeijmakers syndrome (PACS1 neurodevelopmental disorder): seven novel patients and a review. Genes (Basel). 2021;12:738.

Martinez-Monseny A, Bolasell M, Arjona C, Martorell L, Yubero D, Arsmtrong J, et al. Mutation of PACS1: the milder end of the spectrum. Clin Dysmorphol. 2018;27:148–50.

Hoshino Y, Enokizono T, Imagawa K, Tanaka R, Suzuki H, Fukushima H, et al. Schuurs-Hoeijmakers syndrome in two patients from Japan. Am J Med Genet A. 2019;179:341–3.

Thomas G, Aslan JE, Thomas L, Shinde P, Shinde U, Simmen T. Caught in the act-protein adaptation and the expanding roles of the PACS proteins in tissue homeostasis and disease. J Cell Sci. 2017;130:1865–76.

Miyake N, Ozasa S, Mabe H, Kimura S, Shiina M, Imagawa E, et al. A novel missense mutation affecting the same amino acid as the recurrent PACS1 mutation in Schuurs-Hoeijmakers syndrome. Clin Genet. 2018;93:929–30.

Holder JL Jr, Lotze TE, Bacino C, Cheung SW. A child with an inherited 0.31 Mb microdeletion of chromosome 14q32.33: further delineation of a critical region for the 14q32 deletion syndrome. Am J Med Genet A. 2012;158A:1962–6.